Medtronic Inc. (NYSE:MDT) won CE Mark approval in the European Union for its new drug-eluting coronary stent system.
The Minneapolis-based medical device giant said the device’s new design gives it superior mobility within a patient’s vasculature.
Medtronic said the stent’s new "continuous sinusoid technology" gives the device significantly more deliverability than alternative stents when administered with the its MicroTrac delivery system.
Medtronic combined the cytostatic anti-proliferative drug zotarolimus and its biocompatible BioLinx polymer of its original Resolute drug-eluting stent with the continuous sinusoid technology to create the Resolute Integrity stent.
